Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor's immune cells attack the recipient's tissues.

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: Download ...

In the new study, Paz and her collaborators tested a stem cell therapy under development by SanBio. One month after rats had a stroke, the scientists injected the modified human stem cells into ...

Stem cell therapy has come a long way since its early days. As an athlete who has undergone it twice, I know that the ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...